Zinger Key Points
- Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks.
- The EU approved AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, reducing the risk of death by 27% in ADRIATIC Phase 3 trial.
- Our government trade tracker caught Pelosi’s 169% AI winner. Discover how to track all 535 Congress member stock trades today.
On Monday, AstraZeneca Plc AZN released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and safety of eneboparatide in adults with chronic hypoparathyroidism.
The study showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical significance at 24 weeks in adults with chronic hypoparathyroidism (HypoPT) compared to placebo.
The primary endpoint is a composite of normalization of albumin-adjusted serum calcium levels and independence from active vitamin D and oral calcium therapy.
HypoPT is a rare endocrine disease caused by a deficiency of PTH and is characterized by impaired regulation of calcium and phosphate levels in the blood. Eneboparatide was well tolerated.
After the 24-week randomized treatment period, all patients receive eneboparatide in the ongoing long-term extension until 52 weeks. Full efficacy and safety data will be analyzed at 52 weeks.
Concurrently, AstraZeneca and Alteogen entered into an exclusive license agreement for ALT-B4, a hyaluronidase utilizing Hybrozyme platform technology.
Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialize subcutaneous formulations of several oncology assets.
Alteogen will be responsible for the clinical and commercial supply of ALT-B4 to AstraZeneca.
AstraZeneca will pay Alteogen an upfront payment and additional payments upon achieving specific development, regulatory, and sales-related milestones. Additionally, Alteogen will receive royalties on the sales of the commercialized products.
On Monday, the European Union approved AstraZeneca’s Imfinzi (durvalumab) as monotherapy for adults with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy.
The approval is based on results from the ADRIATIC Phase 3 trial.
The trial showed that Imfinzi reduced the risk of death by 27% compared to placebo.
The estimated median overall survival was 55.9 months for Imfinzi versus 33.4 months for placebo. An estimated 57% of patients treated with Imfinzi were alive at three years compared to 48% for placebo.
Imfinzi also reduced the risk of disease progression or death by 24% versus placebo.
The median progression-free survival (PFS) was 16.6 months for Imfinzi versus 9.2 months for placebo. An estimated 46% of patients treated with Imfinzi had not experienced disease progression at two years compared to 34% for placebo.
Earlier on Monday, AstraZeneca agreed to acquire cell therapy focused-EsoBiotec SA for up to $1 billion.
Price Action: At the last check on Monday, AZN stock was down 1.04% to $76.78 during the premarket session.
Read Next:
Image by Robert Way via Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
